Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 9;87(1):13-17.
doi: 10.1097/MS9.0000000000002796. eCollection 2025 Jan.

Beyond blood transfusions: exploring iron chelation therapies in transfusion-dependent beta-thalassemia

Muhammad Talha  1 , Mohammad Haris Ali  1 , Sonia Hurjkaliani  2 , Zainab Syyeda Rahmat  2 , Haleema Sadia  3 , Md Al Hasibuzzaman  4 , Ahsan Ul Qayyum Uzair  1
Affiliations
Editorial

Beyond blood transfusions: exploring iron chelation therapies in transfusion-dependent beta-thalassemia

Muhammad Talha et al. Ann Med Surg (Lond). .

Abstract

Introduction: Abnormal hemoglobin, or hemoglobinopathy, affects about 7% of the global population. Major hemoglobinopathies like beta-thalassemia and sickle cell disease require regular blood transfusions, leading to chronic iron overload. This review examines the efficacy and safety of deferiprone, an oral iron chelator, in managing iron overload in pediatric patients with transfusion-dependent conditions.

Methods: Data were sourced from PubMed, Google Scholar, and relevant articles, focusing on randomized controlled trials (RCTs) published between 2010 and 2023. The search terms included "deferiprone," "iron chelation," "transfusion," "iron overload," "hemoglobinopathies," and "thalassemia." Three RCTs met the inclusion criteria, involving 521 pediatric patients.

Results: The START trial demonstrated that early-start deferiprone significantly reduced iron load compared to placebo, with no severe adverse events. The DEEP-2 study found deferiprone non-inferior to deferasirox in terms of efficacy and safety. Another trial highlighted the benefits of early deferiprone therapy in delaying iron overload symptoms without serious side effects. Common adverse effects included pyrexia, nasopharyngitis, and decreased neutrophil count, but no significant differences in growth parameters, creatinine, or prolactin levels were observed.

Conclusion: Deferiprone shows significant promise in managing iron overload in pediatric patients, with comparable effectiveness to existing therapies and a favorable safety profile. Its oral administration is advantageous for young children. However, long-term studies are needed to fully understand its safety and efficacy. Addressing challenges such as patient compliance and adverse effects through education, personalized medicine, and advanced monitoring techniques can further improve treatment outcomes for beta-thalassemia patients.

Keywords: FDA-approved; children; deferiprone; infants; transfusion-induced beta-thalassemia (TBT).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1.
Figure 1.
Deferiprone mechanism of action.
See this image and copyright information in PMC

References

    1. Maggio A, Kattamis A, Felisi M, et al. . Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol 2020;7:e469–e478. - PubMed
    1. Kattamis A, Forni GL, Aydinok Y, et al. . Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol 2020;105:692–703. - PMC - PubMed
    1. Cianciulli P. Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis 2009;1:e2009034. - PMC - PubMed
    1. Belmont A, Kwiatkowski JL. Deferiprone for the treatment of transfusional iron overload in thalassemia. Expert Rev Hematol 2017;10:493–503. - PubMed
    1. Elalfy MS, Hamdy M, Adly A, et al. . Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). Am J Hematol 2023;98:1415–24. - PubMed

Publication types

LinkOut - more resources